胰高血糖素样肽-1受体激动剂致2型糖尿病患者不良反应文献分析

Literature analysis of adverse reactions induced by GLP-1RA in patients with type 2 diabetes mellitus

目的 分析胰高血糖素样肽-1受体激动剂(GLP-1RA)致2型糖尿病患者药品不良反应(ADR)的发生特点和规律,为临床合理用药提供依据。方法 检索Cochrane Library、PubMed、Embase、中国知网(CNKI)、万方数据知识服务平台中GLP-1RA致2型糖尿病患者ADR个案报道并整理分析。结果 收集个案报道102例,GLP-1RA引发ADR未见显著性别差异,ADR多发生于用药3个月内,可引发皮肤、皮下组织系统、胃肠系统、肾脏系统、心血管系统等多系统疾病。结论 临床应用GLP-1RA过程中应加强用药监护,尤其对既往存在相关基础疾病的患者,以防严重ADR发生。

Objective To analyze the characteristics and rules of ADRs in patients with type 2 diabetes mellitus caused by GLP-1RA,so as to provide basis for clinical rational drug use.Methods The ADR case reports of patients with type 2 diabetes caused by GLP-1RA in Cochrane Library,PubMed,Embase,CNKI and Wanfang databases were retrieved and analyzed.Results A total of 102 cases were collected and reported.There was no significant gender difference in ADR caused by GLP-1RA.ADR mostly occurred within 3 months of medication and could cause skin,subcutaneous tissue system,gastrointestinal system,renal system,cardiovascular system and other multi system diseases.Conclusion During the clinical application of GLP-1RA,drug monitoring should be strengthened,especially for patients with previous related basic diseases,in order to prevent serious ADR.